Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy.
Among shigellas isolated from patients in England and Wales in 2002, 10% of subgroups A, B and C, and 13% of subgroup D (Shigella sonnei), were resistant to nalidixic acid. As a consequence, should antimicrobial therapy be indicated, the efficacy of nalidixic acid as the preferred treatment for children with bacillary dysentery has been jeopardised.
Cheasty
T
T
Health Protection Agency, Specialist and Reference Microbiology Division, Laboratory of Enteric Pathogens, London, UK.
Day
M
M
Threlfall
E J
EJ
D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D024881:Drug Resistance, Bacterial; D004405:Dysentery, Bacillary / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D004739:England / Q000453:epidemiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D012760:Shigella / Q000187:drug effects*; D012764:Shigella sonnei / Q000187:drug effects; D014852:Wales / Q000453:epidemiology
D000890:Anti-Infective Agents; D009268:Nalidixic Acid